Clinical Comparison of Three Sample-to-Answer Systems for Detecting SARS-CoV-2 in B.1.1.7 Lineage Emergence
Ming-Jr Jian,Hsing-Yi Chung,Chih-Kai Chang,Jung-Chung Lin,Kuo-Ming Yeh,Chien-Wen Chen,Shih-Yi Li,Shan-Shan Hsieh,Ming-Tsan Liu,Ji-Rong Yang,Sheng-Hui Tang,Cherng-Lih Perng,Feng-Yee Chang,Hung-Sheng Shang
DOI: https://doi.org/10.2147/IDR.S328327
2021-08-17
Infection and Drug Resistance
Abstract:Ming-Jr Jian, 1, &ast Hsing-Yi Chung, 1, &ast Chih-Kai Chang, 1 Jung-Chung Lin, 2 Kuo-Ming Yeh, 2 Chien-Wen Chen, 3 Shih-Yi Li, 1 Shan-Shan Hsieh, 1 Ming-Tsan Liu, 4 Ji-Rong Yang, 4 Sheng-Hui Tang, 1 Cherng-Lih Perng, 1 Feng-Yee Chang, 2 Hung-Sheng Shang 1 1 Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China; 2 Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China; 3 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China; 4 Centers for Disease Control, Taipei, Taiwan, Republic of China &astThese authors contributed equally to this work Correspondence: Hung-Sheng Shang; Feng-Yee Chang Email ; Purpose: Accurate molecular diagnostic assays for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, are needed for epidemiology studies and to support infection-control measures. We evaluated the analytical sensitivity and clinical performance of three sample-to-answer molecular-diagnostics systems for detecting SARS-CoV-2 using 325 nasopharyngeal swab clinical samples from symptomatic patients. Methods: The BioFire Respiratory Panel 2.1 (RP2.1), cobas Liat SARS-CoV-2 and Influenza A/B, and Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV platforms, which have been granted emergency-use authorization by the US FDA, were tested and compared. Results: The positive percent agreement, negative percent agreement, and overall percent agreement among the three point of care testing systems were 98– 100%, including for the wild-type SARS-CoV-2 (non-B.1.1.7) and a variant of concern (B.1.1.7). Notably, the BioFire RP2.1 may fail to detect the SARS-CoV-2 S gene in the B.1.1.7 lineage because of the spike protein mutation. Conclusion: All three point of care testing platforms provided highly sensitive, robust, and almost accurate results for rapidly detecting SARS-CoV-2. These automated molecular diagnostic assays can increase the effectiveness of control and prevention measures for infectious diseases. Keywords: COVID-19, SARS-CoV-2, point of care testing, molecular diagnostics, sample to answer, variant of concern A cluster of pneumonia cases of unknown etiology was reported in December of 2019 and was confirmed to be the novel coronavirus 2019 (2019-nCoV). 1–3 By July 2021, more than 200 million reported cases of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were reported and were associated with over four million deaths globally ( https://covid19.who.int/ ). Accurate and reliable molecular-diagnostic assays for detecting SARS-CoV-2 may help clinicians better understand the etiology of suspected SARS-CoV-2 infection. 4 Nucleic acid-amplification tests are highly sensitive and specific and are considered as the gold standard for SARS-CoV-2 diagnosis. 5–7 A correct SARS-CoV-2 diagnosis contributes to disease treatment and regimens. Although many molecular diagnostic platforms have become available to meet the enormous demands during the COVID-19 pandemic, 8–10 the clinical performance of these diagnostic methods has not been thoroughly evaluated. Affordable point of care testing (POCT) kits serve as alternative diagnostic methods but are limited by their availability, although they are widely used to test the general public. 11 , 12 Recently, a SARS-CoV-2 test was added to the Liat SARS-CoV-2 and Influenza A/B (Roche Molecular Systems, Inc., Pleasanton, CA, USA), Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV (Cepheid, Sunnyvale, CA, USA), and BioFire Respiratory Panel 2.1 (RP2.1; BioFire Diagnostics, LLC; Salt Lake City, UT, USA) tests, which are commonly used multiplex PCR panels for diagnosing upper respiratory tract infections by multiple co-existing respiratory viruses. Importantly, new SARS-CoV-2 variants of concern (VOCs) may enhance virus transmissibility and/or disease severity, as well as diagnostic and/or treatment failure. 13 SARS-CoV-2 lineages carrying the a -Abstract Truncated-
pharmacology & pharmacy,infectious diseases